K. B. McCredie

2.2k total citations
52 papers, 1.7k citations indexed

About

K. B. McCredie is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, K. B. McCredie has authored 52 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 17 papers in Oncology and 8 papers in Genetics. Recurrent topics in K. B. McCredie's work include Acute Myeloid Leukemia Research (21 papers), Neutropenia and Cancer Infections (12 papers) and Chronic Myeloid Leukemia Treatments (8 papers). K. B. McCredie is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Neutropenia and Cancer Infections (12 papers) and Chronic Myeloid Leukemia Treatments (8 papers). K. B. McCredie collaborates with scholars based in United States, United Kingdom and Australia. K. B. McCredie's co-authors include Emil J. Freireich, Michael J. Keating, Hagop M. Kantarjian, Moshe Talpaz, Terry L. Smith, E. J. Freireich, Elihu H. Estey, Ronald S. Walters, Ann Cork and R S Walters and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

K. B. McCredie

52 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. B. McCredie United States 22 1.1k 444 439 432 329 52 1.7k
Gunnar Öberg Sweden 27 1.3k 1.2× 453 1.0× 484 1.1× 279 0.6× 319 1.0× 59 2.1k
J Cahn France 22 1.2k 1.0× 392 0.9× 216 0.5× 364 0.8× 282 0.9× 70 1.6k
Tapani Ruutu Finland 22 1.1k 1.0× 189 0.4× 361 0.8× 429 1.0× 456 1.4× 55 1.7k
M. J. Barnett Canada 20 676 0.6× 388 0.9× 243 0.6× 178 0.4× 173 0.5× 43 1.3k
MR O’Donnell United States 16 982 0.9× 358 0.8× 208 0.5× 405 0.9× 107 0.3× 25 1.4k
Nadežda Basara Germany 23 1.4k 1.2× 520 1.2× 312 0.7× 610 1.4× 179 0.5× 70 2.1k
JH Antin United States 24 1.8k 1.6× 566 1.3× 383 0.9× 307 0.7× 475 1.4× 50 2.8k
N. K. C. Ramsay United States 26 1.1k 1.0× 384 0.9× 260 0.6× 312 0.7× 153 0.5× 37 1.8k
G. Brehm Germany 13 1.1k 1.0× 478 1.1× 266 0.6× 165 0.4× 144 0.4× 23 1.9k
Kazuo Dan Japan 22 829 0.7× 470 1.1× 369 0.8× 142 0.3× 355 1.1× 93 1.8k

Countries citing papers authored by K. B. McCredie

Since Specialization
Citations

This map shows the geographic impact of K. B. McCredie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. B. McCredie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. B. McCredie more than expected).

Fields of papers citing papers by K. B. McCredie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. B. McCredie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. B. McCredie. The network helps show where K. B. McCredie may publish in the future.

Co-authorship network of co-authors of K. B. McCredie

This figure shows the co-authorship network connecting the top 25 collaborators of K. B. McCredie. A scholar is included among the top collaborators of K. B. McCredie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. B. McCredie. K. B. McCredie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kurzrock, Razelle, Hagop M. Kantarjian, CA Koller, et al.. (1991). 2-Chlorodeoxyadenosine: A new anticancer agent in lymphoid malignancies. 43(3). 253–258. 3 indexed citations
2.
Talpaz, Moshe, Michael J. Keating, Elihu H. Estey, et al.. (1991). Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 68(6). 1201–1207. 34 indexed citations
3.
Estey, Elihu H., Razelle Kurzrock, Moshe Talpaz, et al.. (1991). Effects of low doses of recombinant human granulocyte‐macrophage colony stimulating factor (GM‐CSF) in patients with myelodysplastic syndromes. British Journal of Haematology. 77(3). 291–295. 56 indexed citations
4.
Estey, Elihu H., K. B. McCredie, Michael J. Keating, et al.. (1990). Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors. 42(3). 156–161. 2 indexed citations
5.
Keating, Michael J., Elihu H. Estey, Susan O’Brien, et al.. (1990). Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer. 65(1). 5–8. 38 indexed citations
7.
Baron, E. J., et al.. (1988). Hansenula anomala Fungemia. Clinical Infectious Diseases. 10(6). 1182–1186. 51 indexed citations
8.
Dreizen, Samuel, K. B. McCredie, G. P. Bodey, & Michael J. Keating. (1988). Mucocutaneous herpetic infections during cancer chemotherapy. Postgraduate Medicine. 84(2). 181–190. 6 indexed citations
9.
Walters, Ronald S., Michael J. Keating, Moshe Talpaz, et al.. (1987). Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer. 60(8). 1708–1712. 21 indexed citations
10.
Chang, Kun, W. T. Schroeder, Michael J. Siciliano, et al.. (1987). The localization of the human myeloperoxidase gene is in close proximity to the translocation breakpoint in acute promyelocytic leukemia.. PubMed. 1(5). 458–62. 41 indexed citations
11.
Kantarjian, Hagop M., Michael J. Keating, Moshe Talpaz, et al.. (1987). Chronic myelogenous leukemia in blast crisis. The American Journal of Medicine. 83(3). 445–454. 221 indexed citations
12.
Estey, Elihu H., M Keating, Terry L. Smith, et al.. (1984). Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.. Journal of Clinical Oncology. 2(2). 102–106. 11 indexed citations
13.
Bickers, J., Robert S. Benjamin, Harry Wilson, et al.. (1981). Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.. PubMed. 65(5-6). 427–30. 11 indexed citations
14.
Verma, Dharmvir S., Gary Spitzer, Axel R. Zander, et al.. (1980). The kinetics of colony-stimulating activity elaboration from human bone marrow cells by immunoadjuvants: Interactions between light density adherent and nonadherent cells in vitro. Leukemia Research. 4(4). 371–383. 7 indexed citations
15.
Benjamin, Robert S., Michael J. Keating, Kenneth D. Swenerton, S S Legha, & K. B. McCredie. (1979). Clinical studies with rubidazone.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 63(5). 925–9. 10 indexed citations
16.
McCredie, K. B., et al.. (1978). Refractory acute leukaemia in adults treated with sequential colaspase and high-dose methotrexate. BMJ. 2(6140). 791–793. 12 indexed citations
17.
Brown, N, et al.. (1977). Pharmacologic studies of continuous infusion of arabinosylcytosine by liquid infusion system. Clinical Pharmacology & Therapeutics. 22(3). 371–374. 14 indexed citations
18.
Rodríguez, V., Gerald P. Bodey, K. B. McCredie, & E. J. Freireich. (1974). Protected environments (PE) and prophylactic antibiotics in remission induction therapy of adults with acute leukemia. Proceedings of the American Association for Cancer Research. 15. 1 indexed citations
19.
McCredie, K. B., Jeane P. Hester, E. J. Freireich, Geoffrey M. Brittin, & Carlos Vallejos. (1974). Platelet and leukocyte transfusions in acute leukemia. Human Pathology. 5(6). 699–708. 21 indexed citations
20.
O’Neill, Barry James, et al.. (1970). MIXED LEUKAEMIA: A REPORT OF THREE CASES. The Medical Journal of Australia. 2(13). 586–591. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026